Unusual treatment of Kasabach–Merritt syndrome secondary to hepatic hemangioma: embolization with bleomycin [Ungewöhnliche Behandlung eines Kasabach-Meritt Syndroms als Folge eines Hämangioms der Leber: Embolisation mit Bleomycin]

Bozkaya H.Cinar C.Ünalp Ö.V.Parildar M.Oran I.2019-10-272019-10-2720150043-5325https://doi.org/10.1007/s00508-014-0675-5https://hdl.handle.net/11454/25892Kasabach–Merritt syndrome (KMS) is a rare complication of cavernous hemangiomas characterized with anemia, thrombocytopenia, and consumption coagulopathy. This syndrome usually develops due to superficial soft tissue hemangiomas in infancy and childhood. KMS developing secondarily to hepatic hemangioma is very rare. In this report, we aimed to present the treatment of KMS developing secondarily to giant cavernous hemangioma of the liver with transarterial chemoembolization using bleomycin © 2014, Springer-Verlag Wien.en10.1007/s00508-014-0675-5info:eu-repo/semantics/closedAccessBleomycinKasabach–Merritt syndromeLipiodolLiver hemangiomasTransarterial chemoembolizationUnusual treatment of Kasabach–Merritt syndrome secondary to hepatic hemangioma: embolization with bleomycin [Ungewöhnliche Behandlung eines Kasabach-Meritt Syndroms als Folge eines Hämangioms der Leber: Embolisation mit Bleomycin]Article12711.Dec48849025471004Q2